The massive EPS beat and raised gross margin guidance, combined with the Sanofi Development Balance repayment that will structurally increase collaboration profits from Q3, create a strong positive catalyst. Monitor the Q3 2026 report for the first full quarter of post-repayment collaboration revenue and any updates on the cemdisiran PDUFA date in November 2026.
Price Chart
Executive Summary
Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% YoY), driven by strong Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%) sales. The Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3, and the company raised its full-year guidance on gross margins and narrowed R&D and SG&A ranges. The massive EPS beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $4.29B (+17% YoY), above $3.83B consensus
- Non-GAAP EPS $14.29 vs consensus $10.20 (+40.1% beat)
- GAAP EPS $12.23 (includes $1.02 negative IPR&D impact)
- Dupixent global net sales +38% to $6.0B; EYLEA HD U.S. +52% to $596M; Libtayo global +30% to $489M
- Sanofi Development Balance fully repaid as of Q2 end, boosting collaboration profits from Q3
- Full-year 2026 guidance: GAAP gross margin raised to 78-79% (from 77-78%); non-GAAP R&D narrowed to $5.95-6.05B; GAAP SG&A narrowed to $2.83-2.96B
- Share repurchases of $1.2B in Q2, $2.0B in H1 2026; $2.5B remaining under buyback programs
- Cemdisiran NDA accepted under FDA priority review for gMG with target action date Nov 2026
Financial Impact
Non-GAAP EPS beat consensus by 40.1% ($14.29 vs $10.20); revenue beat by $460M (12% above $3.83B consensus)
Risk Factors
- GAAP net income declined 7% YoY due to $127M IPR&D charge and higher tax rate (15.1% vs 8.4%)
- EYLEA franchise U.S. sales declined 12% YoY as EYLEA HD partially cannibalizes EYLEA
- Fianlimab Phase 3 melanoma trial missed primary endpoint (PFS vs pembrolizumab)
- Temporary manufacturing interruption at Limerick facility impacted Q2 gross margins (GAAP 78% vs 83% YoY)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335868 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $800.70 | ▲ +18.33% | ▲ +13.88% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access